Design and synthesis of promiscuous high-affinity monoamine transporter ligands: Unraveling transporter selectivity

被引:15
作者
Greiner, E
Boos, TL
Prisinzano, TE
De Martino, MG
Zeglis, B
Dersch, CM
Marcus, J
Partilla, JS
Rothman, RB
Jacobson, AE
Rice, KC [1 ]
机构
[1] NIDDK, Med Chem Lab, NIH, DHHS, Bethesda, MD 20892 USA
[2] NIDA, Addict Res Ctr, Clin Psychopharmacol Sect, NIH,DHHS, Baltimore, MD 21224 USA
[3] Univ Iowa, Coll Pharm, Iowa City, IA 52242 USA
[4] Univ Roma La Sapienza, Fac Pharm, Dept Pharmaceut Studies, I-00185 Rome, Italy
关键词
D O I
10.1021/jm050766f
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of 4- [2-[bis(4-fluorophenyl)methoxy]ethyl]-piperidines and 4-[2-[(bisphenyl)methoxy] ethyl] piperidines with different types of substituents in the phenylpropyl side-chain were synthesized and examined for their ability to bind to the dopamine transporter (DAT), the serotonin transporter (SERT), and the norepinephrine transporter (NET). All of the compounds showed high binding affinities for the DAT in the low to subnanomolar range. Their ability to bind to the SERT and the NET, while maintaining their high affinity for the DAT, could be altered by substitution in positions C2 and C3 of the phenylpropyl side-chain. This approach gave rise to a new set of compounds with selectivity for the DAT, the DAT and the SERT, or the DAT and the NET. Six compounds (7, 9, 11, 12, 14, and 20) with relatively low SERT/DAT ratios were selected for additional study in biogenic amine uptake inhibition assays based on the biogenic amine transporter binding results. Some of the new ligands can serve as pharmacological tools to block DAT or DAT and another transporter simultaneously.
引用
收藏
页码:1766 / 1772
页数:7
相关论文
共 39 条
[1]   Alterations in serotonergic responsiveness during cocaine withdrawal in rats: Similarities to major depression in humans [J].
Baumann, MH ;
Rothman, RB .
BIOLOGICAL PSYCHIATRY, 1998, 44 (07) :578-591
[2]  
BERGMAN J, 1989, J PHARMACOL EXP THER, V251, P150
[3]   Synthesis and monoamine transporter affinity of 3'-analogs of 2-β-carbomethoxy-3-β-(4'-iodophenyl)tropane (β-CIT) [J].
Bois, F ;
Baldwin, RM ;
Kula, NS ;
Baldessarini, RJ ;
Innis, RB ;
Tamagnan, G .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (09) :2117-2120
[4]  
BOOS TL, IN PRESS BIOORG MED
[5]   Cocaine abuse: hard knocks for the dopamine hypothesis? [J].
Caine, SB .
NATURE NEUROSCIENCE, 1998, 1 (02) :90-92
[6]   Pharmacotherapies for treatment of cocaine abuse: Preclinical aspects [J].
Carroll, FI ;
Howell, LL ;
Kuhar, MJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (15) :2721-2736
[7]   Structure-activity relationship studies of highly selective inhibitors of the dopamine transporter:: N-benzylpiperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine [J].
Greiner, E ;
Prisinzano, T ;
Johnson, EM ;
Dersch, CM ;
Marcus, J ;
Partilla, JS ;
Rothman, RB ;
Jacobson, AE ;
Rice, KC .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (08) :1465-1469
[8]  
HOLMES HL, 1955, ORG SYNTH, V3, P300
[9]   Cocaine use and high-risk sexual behavior among STD clinic patients [J].
Hser, YI ;
Chou, CP ;
Hoffman, V ;
Anglin, MD .
SEXUALLY TRANSMITTED DISEASES, 1999, 26 (02) :82-86
[10]   Development of long-acting dopamine transporter ligands as potential cocaine-abuse therapeutic agents: Chiral hydroxyl-containing derivatives of 1[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl) piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine [J].
Hsin, LW ;
Dersch, CM ;
Baumann, MH ;
Stafford, D ;
Glowa, JR ;
Rothman, RB ;
Jacobson, AE ;
Rice, KC .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (06) :1321-1329